Vaginal cancer

disease
On this page

Also known as cancer of vaginamalignant neoplasm of the vaginamalignant neoplasm of vaginamalignant tumor of the vaginamalignant tumor of vaginamalignant tumour of the vaginamalignant tumour of vaginamalignant vagina neoplasmmalignant vagina tumormalignant vagina tumourmalignant vaginal neoplasmmalignant vaginal tumormalignant vaginal tumourvagina cancervagina neoplasmvaginal tumorvaginal tumour

Summary

Vaginal cancer (MONDO:0001402) is a cancer (an umbrella term covering 5 Mondo subtypes) and 103 clinical trials. Top therapeutic interventions include paclitaxel, human papillomavirus, l1 protein virus like particles, and belzutifan. A subtype of female reproductive organ cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Umbrella term: 5 Mondo subtypes
  • Clinical trials: 103

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namevaginal cancer
Mondo IDMONDO:0001402
MeSHD014625
DOIDDOID:119
ICD-10-CMC52
ICD-11798353632
NCITC7410
SNOMED CT363445000
UMLSC0042237
MedGen12040
Anatomy (UBERON)UBERON:0000996
Is cancer (heuristic)yes

Also known as: cancer of vagina · malignant neoplasm of the vagina · malignant neoplasm of vagina · malignant tumor of the vagina · malignant tumor of vagina · malignant tumour of the vagina · malignant tumour of vagina · malignant vagina neoplasm · malignant vagina tumor · malignant vagina tumour · malignant vaginal neoplasm · malignant vaginal tumor · malignant vaginal tumour · vagina cancer · vagina neoplasm · vaginal tumor · vaginal tumour

Disease family

This is a subtype of female reproductive organ cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmcancerreproductive system cancerfemale reproductive organ cancervaginal cancer

Related subtypes (8): vulva cancer, fallopian tube cancer, uterine cancer, adenocarcinofibroma, endometrioid adenocarcinoma, adenosarcoma, ovarian cancer, gestational choriocarcinoma

Subtypes (5): vagina sarcoma, vaginal adenosarcoma, vaginal carcinoma, vaginal germ cell malignant tumor, malignant vaginal mixed epithelial and mesenchymal neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 103.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified53
PHASE219
PHASE115
PHASE312
PHASE1/PHASE24

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04422366PHASE3RECRUITINGEvaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT04895020PHASE3RECRUITINGImmunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
NCT05027776PHASE3RECRUITINGImmunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
NCT00003267PHASE3COMPLETEDPelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer
NCT00033605PHASE3COMPLETEDOctreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
NCT00543543PHASE3COMPLETEDBroad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
NCT00943722PHASE3COMPLETEDA Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
NCT01047345PHASE3COMPLETEDA Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
NCT01087268PHASE3UNKNOWNHyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
NCT03158220PHASE3COMPLETEDImmunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
NCT04425291PHASE3COMPLETEDEvaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT05372016PHASE3COMPLETEDEvaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT04708470PHASE1/PHASE2ACTIVE_NOT_RECRUITINGA Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
NCT05639972PHASE1/PHASE2RECRUITINGE7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
NCT05686226PHASE2RECRUITINGE7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
NCT05979610PHASE2RECRUITINGUsing Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
NCT06023862PHASE2RECRUITINGA Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
NCT06677190PHASE2RECRUITINGBelzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
NCT00002562PHASE2COMPLETEDPaclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
NCT00005941PHASE2COMPLETEDPeripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer
NCT00275353PHASE2COMPLETEDEffectiveness of an Individualized Symptom Education Program (ISEP)
NCT00381888PHASE2COMPLETEDFondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
NCT00520598PHASE2COMPLETEDBroad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
NCT00545792PHASE2COMPLETEDSafety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
NCT00551187PHASE2COMPLETEDA Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
NCT00905658PHASE2UNKNOWNNutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer
NCT00941070PHASE2COMPLETEDTriapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
NCT01079832PHASE2COMPLETEDStereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
NCT01097239PHASE1/PHASE2WITHDRAWNExamining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer
NCT01399658PHASE2COMPLETEDImage-Guided Gynecologic Brachytherapy
NCT01585428PHASE2COMPLETEDImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
NCT01764802PHASE2COMPLETEDPsychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
NCT02280811PHASE1/PHASE2COMPLETEDT Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
NCT03439085PHASE2TERMINATEDDNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
NCT04066894PHASE2TERMINATEDSacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
NCT03634267PHASE1ACTIVE_NOT_RECRUITINGMRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
NCT03968406PHASE1RECRUITINGTalazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT06544720PHASE1RECRUITINGSCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
NCT00002949PHASE1COMPLETEDVinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
NCT00004074PHASE1COMPLETEDInterleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PACLITAXEL44
HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES42
BELZUTIFAN41
DOSTARLIMAB41
FLUDEOXYGLUCOSE F 1841
FONDAPARINUX SODIUM41
OCTREOTIDE ACETATE41
VINORELBINE TARTRATE41
TRIAPINE32
BINTRAFUSP ALFA31
ENTINOSTAT31
EDODEKIN ALFA21
CHEMBL408463501
CHEMBL376481601
CHEMBL572479801